Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 0.61 |
| ▸ | SLC5A1 | P13866 | 9/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.61 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1713370 | 1.00 | SLC5A2 (0.61) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL31070273 | 1.00 | SLC5A2 (0.61) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL19867633 | 1.00 | SLC5A2 (0.61) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL29364802 | 1.00 | SLC5A2 (0.61) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL14307351 | 1.00 | SLC5A2 (0.61) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL19867620 | 1.00 | SLC5A2 (0.61) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL18627151 | 1.00 | SLC5A2 (0.61) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL17802291 | 0.91 | SLC5A2 (0.60) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL1713346 | 0.90 | SLC5A2 (0.59) | SLC5A2SLC5A1 | |
| SCHEMBL19183410 | 0.90 | SLC5A2 (0.59) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112641773-A | Composition containing heterocyclic compound and use thereof | 黄泳华 | 2021-04-13 | — | — | CN | claimed |
| CN-111265512-A | Composition containing a mixture of benzyl benzene derivatives and uses thereof | 黄泳华 | 2020-06-12 | — | — | CN | claimed |
| CN-112641773-A | Composition containing heterocyclic compound and use thereof | 黄泳华 | 2021-04-13 | — | — | CN | disclosed |
| CN-111265512-A | Composition containing a mixture of benzyl benzene derivatives and uses thereof | 黄泳华 | 2020-06-12 | — | — | CN | disclosed |
| US-20140243517-A1 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | ASTRAZENECA AB (SE) | 2014-08-28 | — | — | US | disclosed |
| US-20110201795-A1 | Methods of Producing C-Aryl Glucoside SGLT2 Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-18 | — | — | US | disclosed |
| US-7932379-B2 | Methods of producing C-aryl glucoside SGLT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-26 | — | — | US | disclosed |
| US-7375213-B2 | inhibitors of sodium dependent glucose transporters found in the intestine and kidney (SGLT2), and more particularly to a process of producing such compounds, for example dapagliflozin | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1581543-A4 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-03-19 | — | — | EP | disclosed |
| US-20070238866-A1 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | disclosed |
| EP-1581543-A2 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004063209-A2 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| US-20040138439-A1 | inhibitors of sodium dependent glucose transporters found in the intestine and kidney (SGLT2), and more particularly to a process of producing such compounds, for example 1-C-(substituted diphenylmethane-3-yl)- beta -D-glucopyranose | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238866-A1 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | SLC5A2, SLC5A1, GCG | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 1603/4885 |
| US-20110201795-A1 | Methods of Producing C-Aryl Glucoside SGLT2 Inhibitors | SLC5A2, SLC5A1, GCG | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 1603/4885 |
| US-20040138439-A1 | inhibitors of sodium dependent glucose transporters found in the intestine and kidney (SGLT2), and more particularly to a process of producing such compounds, for example 1-C-(substituted diphenylmethane-3-yl)- beta -D-glucopyranose | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885ADRA2A 2672/4885 |
| US-20140243517-A1 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | SLC5A2, SLC5A1, GCG | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.